Start a Clinical Razor-and-Blade Reimbursement Strategy Consultancy

1. 1

   Define the reimbursement-margin-compression problem

   The specific insight you sell is that a clinical razor-and-blade model faces a risk consumer versions never do: a third-party payer effectively sets the blade price, and as coverage expands, that per-use reimbursement gets squeezed. Make this concrete with the TMS example, where per-session fees over 75 percent of revenue came under pressure as insurance coverage grew. Being the advisor who names and models this risk is your entire wedge, so build the diagnostic that quantifies a client's exposure.

2. 2

   Combine device economics and payer fluency

   The rare and valuable combination is understanding how a device maker's razor-and-blade P&L works and how reimbursement and payer behavior evolve as a treatment gains coverage. You must be able to model what tightening per-use reimbursement does to a client's revenue over several years. This dual literacy is why a device maker hires a specialist rather than a generic strategy firm, so demonstrate both sides clearly in your positioning.

3. 3

   Build scenario and pricing models

   Your deliverable is clarity under uncertainty: models that show how a client's economics change across reimbursement scenarios, and pricing and diversification strategies that reduce the exposure. Build reusable models that turn a client's device and per-use economics into scenarios quickly. Good models are both your product and your efficiency, letting you serve more clients and update as coverage policy shifts.

4. 4

   Advise on diversification and mitigation

   The strategic value is not just naming the risk but helping clients mitigate it: pursuing new indications, diversifying revenue beyond the compressible per-session fee, controlling consumable costs, and timing coverage expansion. Help clients build a model that does not assume today's blade margin holds forever. This forward-looking advice, not just analysis, is what justifies a strategic fee and earns repeat engagements.

5. 5

   Reach device makers early and adjacent industries

   Your clients are clinical device makers with razor-and-blade models, in neurostimulation and beyond, since the pattern also appears in other regulated device categories. Build referral relationships with medtech investors, regulatory consultants, and device executives, and publish on the reimbursement-compression risk to establish authority. The insight transfers across any hardware-plus-recurring-revenue clinical model, so your addressable market extends past neurology. This card is distinct from FDA regulatory consulting, which handles clearance, not pricing and reimbursement strategy.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

Best for: Medical-device strategy and reimbursement professionals who understand both pricing models and payer dynamics

Not for: This is not for a generalist strategy consultant with no reimbursement depth, nor a reimbursement expert with no device-model fluency; the value is both. It is a low-capital, higher-viability advisory, distinct from the FDA/SaMD regulatory consultancy and the PE advisory cards.